IL‐17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review
- 17 February 2021
- journal article
- review article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 34 (2)
- https://doi.org/10.1111/dth.14889
Abstract
Introduction The treatment of moderate to severe plaque psoriasis in patients with history of malignancy is challenging. Objective To review the studies reporting the experience with IL‐17A inhibitors in patients with psoriasis and history of malignancy; secondly, to investigate cancer recurrence in a series of patients with a prior malignancy and plaque psoriasis treated with IL‐17A inhibitors. Methods A systematic literature review and an observational retrospective analysis of patients with history of malignancy and plaque psoriasis treated with IL‐17A inhibitors was performed. Results Five original papers out of 601 were retrieved, reporting a total of 10 patients with a median age of 59 years, interquartile range (IQR) 50‐63. Seven patients were treated with secukinumab, one with ixekizumab and two with both sequentially. Although the stage ranged from in situ to IV stage, most of the cases were early‐stage neoplasm. The IL‐17A inhibitor was initiated after a median of 10 months, interquartile range (IQR) 5‐30 (range 0‐144) from the diagnosis of malignancy. In addition, a series of 12 patients with history of malignancy were identified from the University Hospital of Verona, including 9 cases with cancer in clinical remission and 3 with advanced disease at time of initiating IL‐17 inhibitor. No malignancy recurrence was reported within a median of 12 (IQR 6‐23) and 46 (IQR 36‐48) months follow up in case series from literature and our experience, respectively. Conclusion Data on use of IL‐17A inhibitors in patients with chronic plaque psoriasis and history of malignancy are limited. Registries and proactive pharmacovigilance activities are needed to guide clinical practice.Keywords
This publication has 22 references indexed in Scilit:
- Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal TumorsClinical Cancer Research, 2019
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2019
- IL-17R–EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cellsThe Journal of Experimental Medicine, 2018
- Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapiesJournal of Dermatological Treatment, 2018
- Novel Patents Targeting Interleukin-17A; Implications in Cancer and InflammationRecent Patents on Anti-Cancer Drug Discovery, 2018
- Methodological quality and synthesis of case series and case reportsBMJ Evidence-Based Medicine, 2018
- Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise UpdateAmerican Journal of Clinical Dermatology, 2017
- Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataJournal of the American Academy of Dermatology, 2016
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasisJournal of the American Academy of Dermatology, 2016
- Safety of tumor necrosis factor inhibitor therapy in patients with a prior malignancyInternational Journal of Rheumatic Diseases, 2016